Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer
Conclusions: Nab-PTX may be a later-line chemotherapeutic option for previously treated advanced NSCLC.Chemotherapy
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
More News: Abraxane | Anemia | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Nanotechnology | Non-Small Cell Lung Cancer | Study | Toxicology